SCHEMBL2933259

SCHEMBL2933259

CC(C)C[CH]NC(=O)[C@@H](NC(=O)c1cccnc1)[C@@H](C)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
ADAM17 P78536 1/20 0.46
HTT P42858 1/20 0.43
THRB P10828 1/20 0.43
NPC1 O15118 2/20 0.43
TP53 P04637 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
GPR132 Q9UNW8 2/20 0.42
ALDH1A1 P00352 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
ECE1 P42892 1/20 0.42
KDM4E B2RXH2 1/20 0.42
PREP P48147 1/20 0.41
PLOD2 O00469 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL606550 0.89 CTSL (0.46) LMNAGPR132
SCHEMBL607083 0.88 MKNK1 (0.50) LMNANPC1RAB9A
SCHEMBL2930310 0.81 CTSA (0.48)
SCHEMBL2933261 0.80 EPHX2 (0.51) LMNAADAM17HTTTHRBNPC1
SCHEMBL605464 0.80 LONP1 (0.55) HTTSMN1; SMN2HDAC1HDAC6
SCHEMBL619140 0.79 HDAC8 (0.45) NPC1RAB9A
SCHEMBL610095 0.79 NPC1 (0.52) LMNAHTTNPC1RAB9ASMN1; SMN2
SCHEMBL30037817 0.79 LMNA (0.56) LMNAHTTTHRBNPC1TP53
SCHEMBL2928226 0.78 PSMB5 (0.58) LMNAADAM17HDAC1HDAC6
SCHEMBL2934925 0.78 KDM4E (0.47) LMNAHTTNPC1TP53RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US claimed
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP claimed
US-7468383-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2008-12-23 US claimed
US-20060189806-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2006-08-24 US claimed
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US disclosed
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP disclosed
US-20090075936-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-03-19 US disclosed
US-7468383-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2008-12-23 US disclosed
US-20060189806-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2006-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189806-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 LMNA 742/4885ADAM17 1846/4885HTT 1344/4885
US-20090075936-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 LMNA 742/4885ADAM17 1846/4885HTT 1344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.